A combination Sceptor Breakpoint/ID panel (Johnston Laboratories, Inc., Towson, Md.), which determines interpretive susceptibility results (susceptible, moderately susceptible, and resistant) using two to three selected concentrations of antimicrobial agents, was tested in comparison with full-range Sceptor microdilution MIC panels. The inter-and intralaboratory interpretive reproducibilities for 24 control strains tested in three laboratories on three consecutive days were 97.0 and 95.7%, respectively. 
One of the major roles of the clinical microbiology laboratory is to evaluate the effectiveness of different antimicrobial agents against bacteria as a guide to therapy. Most laboratories perform either the qualitative agar disk diffusion procedure or the quantitative broth microdilution procedure for antimicrobial susceptibility testing, although these may not be the sole methods used. Performance standards for agar disk diffusion and dilution susceptibility tests provide interpretive criteria which relate the zone size or MIC to antimicrobial activity in the form of susceptibility categories (susceptible, intermediate, moderately susceptible, or resistant [6, 7] ). Interpretive results are on the basis ofachievable levels in serum and, for a few specialized antimicrobial agents, in the urinary tract.
The utility of routine reporting of quantitative MIC results in situations other than systemic infections has been a subject of debate and source of confusion between laboratory workers and physicians (4 
RESULTS
Summaries of the reproducibility and equivalency results for breakpoint susceptibility testing from the first phase of this study are shown in Tables 1 and 2 . The overall levels of agreement for intra-and interlaboratory reproducibility were 97.0 and 95.7%, respectively (Table 1) . Most errors were caused by minor discrepancies ranging from 2.0 to 3.9%. The frequencies of major and very major discrepancies were less than 1%.
Comparisons between modal reference MIC and breakpoint interpretive results for each laboratory ( bThe overall percents interpretive agreements, agreements including minor discrepancies, major discrepancies, and very major discrepancies were 94.1, 98.9, 0.6, and 0.5%, respectively.
were included, the level of agreement was greater than 98.0% for all laboratories. Again, major and very major discrepancies were less than 1%.
Comparative results from phase 2 between full-range MIC and breakpoint interpretive data are shown in Tables 3 and 4 . The overall agreement for members of the family Enterobacteriaceae was 97.2% (Table 3 ). The level of agreement when minor discrepancies were included was greater than 98.0%. Among 10 major discrepancies observed (amikacin-S. marcescens, three; nitrofurantoin-E. cloacae, three; nitrofurantoin-P. mirabilis, three; and piperacillin-S. marcescens, a<A total of 51 strains from the family Enterobacteriaceae were evaluated, representing 3,672 organism-antimicrobial agent susceptibility comparisons.
For each antimicrobial agent, 153 organism combinations were tested. b The overall numbers (percents) of interpretive agreements, agreements including minor discrepancies, major discrepancies, and very major discrepancies were 3,571 (97.2), 3,652 (99.4), 10 (0.2). and 10 (0.2). respectively. one), nitrofurantoin was responsible for more than half the errors. Among 10 very major discrepancies noted (cephalothin-S. marcescens, one; chloramphenicol-E. coli, one; chloramphenicol-S. marcescens, one; nalidixic acid-P. mirabilis, three; nalidixic acid-S. marcescens, three; and nitrofurantoin-P. mirabilis, one), nalidixic acid accounted for more than half the errors. No significant antimicrobial agentorganism combination was responsible for major and very major discrepancies.
The overall agreement for the staphylococci was 96.8% (Table 4 ). The level of agreement when minor discrepancies were included was greater than 99.0%. No major discrepancies were observed. All of the very major discrepancies occurred with trimethoprim (methicillin-resistant, coagulase-negative staphylococci, six; methicillin-susceptible, coagulase-negative staphylococci, three) and sulfisoxazole (methicillin-resistant S. aureus, three) and were random in distribution.
DISCUSSION
The Sceptor microdilution MIC system has been shown to be a reliable method for the determination of quantitative antimicrobial susceptibility (3) . In this study, the interpretive agreement obtained using a limited number of antimicrobial agent concentrations (two to three) was shown to be highly reproducible and accurate when compared with full-dilution MIC results. The frequency of minor discrepancies was probably caused by differences between the actual MIC and breakpoint concentrations used to define susceptibility categories. Since most antimicrobial agents tested have a moderately susceptible category, the one doubling dilution variation considered an acceptable range for MIC testing results most often in minor discrepancies. Therefore, the inclusion of minor discrepancies may represent a more realistic level of equivalency when determining interpretive agreement.
In phase 2 of this study, very major discrepancies between members of the family Enterobacteriaceae and nalidixic acid were attributed to false-susceptible results with the Sceptor Breakpoint/ID panels. The problem was identified as a manufacturer's error in the actual concentration of antimicrobial agent in the wells and has been corrected. Among the staphylococci tested, all very major discrepancies were The addition of Breakpoint/ID panels to the Sceptor system offers several advantages. Each panel allows for up to 24 antimicrobial agents with simultaneous susceptibility and identification in a single setup. Because of the selective concentrations of antimicrobial agents present in the wells of the panel, endpoint determinations are distinct and easy to intçrpret. Breakpoint panels can be more cost effective and labor saving than the limited full-range MIC panels in determining a broader spectrum of in vitro activity to a variety of antimicrobial agents. This may be helpful to the pharmacy and medical staff that assess antimicrobial agent usage at their own institution. Even with restrictive antimicrobial agent reporting, the microbiology laboratory can select the most appropriate drug on the basis of antimicrobial activity, cost, and pharmacokinetics. Additional quality control testing will be required, however, to assure the performance of breakpoint panels. Although performed less frequently, full-dilution MIC and minimal bactericidal data are needed in certain situations, such as for patients with infective endocarditis.
In summary, the Sceptor Breakpoint/ID panel was found to be as reliable as the full-range microdilution MIC panel for determining the qualitative antimicrobial agent susceptibility of members of the family Enterobacteriaceae and staphylococci. The versatility of breakpoint panels makes it applicable to a variety of hospital formularies.
